Supernus Provides Regulatory Update for SPN-830
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'
April 8, 2024 10:10 AM EDTJefferies analyst Irene Buhalo reiterated a Buy rating and $40.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN)
The analyst comments "We expect a -5-10% stock reaction after the FDA's rejection of SPN-830 (apomorphine pump) in Parkinson's. Street expectations were fairly low,... More
Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
April 8, 2024 10:09 AM EDTStifel analyst Annabel Samimy reiterated a Hold rating and $38.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).
The analyst comments "SUPN announced that the resubmission review of SPN-830 (apomorphine infusion pump for PD) has been met with another CRL. Specifically, FDA is requesting additional... More
